Immix Biopharma Completes 3rd NXC-201 Engineering Batch At Its U.S. CAR-T Manufacturing Site
Portfolio Pulse from Benzinga Newsdesk
Immix Biopharma has successfully completed the third engineering batch of NXC-201 at its U.S. CAR-T manufacturing site. This completion supports the expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S.
October 16, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immix Biopharma's successful completion of the third NXC-201 batch supports the expansion of its NEXICART-1 clinical trial, potentially leading to positive impacts on the company's stock.
The successful completion of the third NXC-201 batch at Immix Biopharma's U.S. site is a significant milestone for the company. This development supports the expansion of its ongoing NEXICART-1 clinical trial to the U.S., which could potentially lead to increased investor confidence and a positive impact on the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100